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Classically activated microglia (M1) are believed to play a key role in neuronal degeneration in multiple
sclerosis (MS). In this issue of Immunity, Starossomet al. (2012) show thatGalectin-1 exerts a neuroprotective
function through glycosylation-dependent inactivation with M1 cells.Multiple sclerosis (MS) is an inflammatory
disease that affects the central nervous
system (CNS). The pathogenic hallmark
of MS is a presence of focal areas
of inflammatory-mediated demyelination,
breakdown of blood-brain barrier, gliosis,
and axonal damage in brain and spinal
cord (Trapp and Nave, 2008). MS is
a disease based on a breakdown of
self-nonself discrimination in which the
host immune system assume myelin
in the CNS is a foreign antigen and
destroys it. Major supporting evidence
for this autoimmune hypothesis comes
from studies of experimental autoimmune
encephalomyelitis (EAE), a disease
model in animals, which can be induced
by sensitization with CNS antigens such
as myelin proteins or myelin protein
peptides.
In the pathogenesis of EAE, two sets
of antigen-presenting cells (APCs) are
considered to function as key players:
those in the periphery and microglia in
the CNS. Upon encountering myelin
antigen, peripheral APCs mature and
migrate to lymph nodes where they
present antigen to naive T cells. Depend-
ing on the type of cytokines produced by
APCs, T cells differentiate into distinct
effector CD4+ T cell subsets (Th1, Th2,
Th17, and Treg). It is currently believed
that MS is driven by Th1 and Th17 cell
subsets. Upon activation, T cells migrate
to the brain, cross the blood brain barrier,
and mediate myelin destruction in
CNS. In contrast, microglia are resident
macrophages in the CNS and are dis-
tinct from peripheral APCs. Microglia
constantly facilitate immune surveillance
of microenvironment and thus maintain
homeostasis in the CNS. In the quiescent
states, microglia express a low amount ofCD45 and undetectable amounts of
MHC class I and II, CD80, CD86, and
CD40. However, once activated in
response to inflammatory stimuli, micro-
glia upregulate the expression of CD45,
MHC, and costimulatory molecules,
enhance phagocytosis, and gain the
capacity to stimulate the proliferation of
Th1 and Th2 cells. Of note, microglia
can differentiate into different subsets,
classically activated microglia (M1) and
alternatively-activated (M2) microglia.
Whereas M1 microglia are involved
in inflammation-mediated neurotoxicity,
M2 microglia are thought to have neuro-
protective functions. Activated M1 micro-
glia have a major role in the neuronal
degradation in MS (Trapp and Nave,
2008). There is a physical association
between activated M1 microglia and
neuronal cell bodies and their proximal
dendrites in acute gray matter lesions. In
addition, the number of M1 microglia
cells is correlated with the amount of
axonal damage in MS lesions and with
neuronal dysfunction in EAE. Despite
insights provided by the EAE model on
the current understanding of MS as
a primary inflammatory demyelinating
disease (Kang et al., 2010), little is known
about the activation mechanism of M1
microglia in MS.
In this issue of Immunity, Starossom
et al. (2012) identified Galectin-1, an
endogenous glycan-binding protein en-
coded by Lgals1 gene, as a pivotal
regulator of microglia activation (Figure 1).
Galectin-1 promoted deactivation M1
microglia and instead upregulated a
phenotype of M2 microglia activation
through modulation of p38-MAPK, CREB,
and NF-kB signaling pathways, which
eventually prevents neurodegenerationImmunity 37and promotes neuroprotection. The
source of Galectin-1 was astrocytes,
which mainly function as a biochemical
support of endothelial cells that forms
the blood-brain barrier. Indeed, astro-
cytes expressed high amounts of
Galectin-1 during both acute and chronic
phase of EAE. Starossom et al. demon-
strated that Galectin-1 deactivates M1
microglia and inhibits axonal damage in
EAE by showing abundant presence of
M1 microglia and decreased immuno-
reactivity against the neuronal and
axonal marker in the Galectin-1-deficient
Lgals1/ mice. Interactions of multiva-
lent lectin with glycan probably trap
glycoprotein receptors at the cell surface
and prevent their endocytosis, during
which intracellular signaling is prolonged
due to enhanced responsiveness to
extracellular inputs (Ohtsubo et al., 2005;
Partridge et al., 2004). Here, Starossom
et al. show that Galectin-1 bound to
core 2-branched O-glycan of CD45, a
phosphatase that transduces inhibitory
signals for M1 activation (Penninger
et al., 2001), promoted retention of
this glycoprotein on the surface of
microglia cells and prolonged and
augmented its phosphatase activity.
Furthermore, they demonstrated that
administration of exogenous Galectin-1
significantly attenuated EAE disease
severity and decreased microglia activa-
tion in the spinal cord in vivo, suggesting
that targeting the Galectin-1-glycan
axis may represent a new therapeutic
approach for diseases involving inflam-
mation-associated neurodegenedration
in MS.
The hypothesis of MS pathogenesis
based on activated T cell destruction
of myelin was widely accepted because, August 24, 2012 ª2012 Elsevier Inc. 187
Figure 1. Immune Regulation of Microglia Differentiation in MS by Galectin-1
In EAEmodel of wild-typemice, Galectin-1 secreted from astrocytes binds toM1microglia through CD45.
If there is a sufficient amount of Galectin-1, Galectin-1-CD45 interaction traps CD45 at the cell surface and
enhances its phosphatase activity, which negatively regulates M1microglia activation throughmodulation
of p38MAPK, CREB, and NF-kB pathways. Consequently, it leads to the promotion of neuroprotective M2
microglia phenotype. In contrast, Lgals1/mice, which lacks endogenousGalectin-1, enhances classical
microglia activation and promotes axonal damage during EAE.
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rodent EAE model and MS (Sospedra
and Martin, 2005). However, the cause
or essential aspects of the initiating
factors in the human MS is still different
from mouse EAE: the role of microglia
in human MS is considered to be more
important than in EAE (Trapp and Nave,
2008). When the density of T cells was
quantified in cortical MS lesions, there
were only few inflammatory cells and
no perivascular cuffs and phagocytic
macrophages, but many activated micro-
glia (Bø et al., 2003). Notably, cortical
lesions have intact blood-brain barriers
and cortical demyelination occurs
without significant influx of hematogene-
ous leukocytes. Therefore, these reports
provide another convincing hypothesis
that microglia, but not T cells, play
a direct role in cortical demyelination in
human MS. In a new direction of the
work by Starossom et al. (2012), neuro-
protective role of Galectin-1 should be
validated (e.g., negative correlation
between the amount of Galectin-1 and
disease progression) in CNS of human188 Immunity 37, August 24, 2012 ª2012 ElsMS. Molecular mechanism of how
Galectin-1 expression is physiologically
regulated in astrocytes will provide
insight for further understanding of MS
pathogenesis.
Although the study by Starossom
et al. (2012) provided new insights that
underlie the cause of MS, we may still
have a significant hurdle for clinical use
of exogenous Galectin-1 as a therapeutic
tool for MS. Galectin-1 was the first
recognized member of the mammalian
galectin family, showed the widest distri-
bution in mammalian tissues, where it
was relatively abundant, and has been
associated with T cell apoptosis. Galec-
tin-1 contains a carbohydrate recogni-
tion domain (CRD) characteristic for
the Galectin family. The b sheet motif of
Galectin-1 CRD shares a highly con-
served structural homology with other
galectins such as Galectin-3. Although,
so far, there is no indication of functional
redundancy between Galectin-1 and
Galectin-3 in vivo, this is considered
mainly because of their distinct tissue
distribution and subcellular localiza-evier Inc.tion rather than differences in their
carbohydrate-binding specificities (Leffler
et al., 2004). Nevertheless, in different
ways, a number of Galectin family
members have been associated with
the control of CNS macrophages and
microglia. Galectin-3 is upregulated in
microglia in a model of traumatic brain
injury and favors myelin phagocytosis. In
contrast, Galectin-9 signals through
Tim-3 on CD11b+ CNS cells to stimulate
innate immunity (Anderson et al., 2007).
Furthermore, both Galectin-3 and -4 are
highly expressed by oligodendrocytes,
which contribute to myelination. It is of
interest that these reports suggest just
a slight but significant difference of
carbohydrate specificities among dif-
ferent Galectins can give rise to opposite
effects on MS pathogenesis. Compre-
hensive and detail profiling of Galectin
carbohydorate ligands will be required
in the research field of MS. Moreover,
interaction of Galectin-1 with other
ligands than CD45 on microglia should
be carefully considered. Functional
specificity of Galectin-1 in the interaction
with CD45 will be of particular value
when designing its therapeutic strategy.
Developing alternative antibodies spe-
cific to the core 2-branched O-glycan
of CD45 will improve nonspecific recog-
nition of Galectin-1. Regardless, the
present study by Starossom et al. (2012)
highlights the importance of Galectin-1
in adjustment of immune balance from
neurodegeneration to neuroprotection,
which may help in our understanding of
pathogenesis in human MS.REFERENCES
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In this issue of Immunity, Scheiermann et al. (2012) demonstrate that circadian regulation of the expression of
endothelial cell adhesion molecules via adrenergic innervation of local vasculature promotes clinically signif-
icant changes in leukocyte homing and bone marrow engraftment.One of the most beneficial aspects of
the immune response is the spatial preci-
sion with which it is focused. Even the
innate immune response (with the excep-
tion of septic shock and systemic inflam-
matory response syndrome) is generally
exquisitely localized. Indeed, even as I
type this draft with an ingrown fingernail,
all the tumor, rubor, calor, and dolor is
confined to the left side of the nail bed
of the affected finger. Degranulated
dermal mast cells, chemokine-secreting
macrophages, and activated endothelial
cells in the affected vascular bed are
recruiting neutrophils to kill bacteria and
start the process of wound repair. Local
circulation on the other side of my finger
goes on blissfully unaware. Direct obser-
vations of leukocyte emigration at sites
of inflammation in vivo reveal that, even
within the inflamed tissue, leukocytes
preferentially emigrate from a restricted
set of postcapillary venules. It is a good
thing for us as a species that control of
inflammation is so local—if neutrophils
were pouring into my alveoli as fast as
they were entering the tip of my finger,
I’d be deathly ill from pneumonia before I
finished the next paragraph.
Research on the inflammatory re-
sponse has focused on mechanisms reg-
ulating local control. With the discovery of
inflammation-induced adhesion andsignaling molecules on endothelial cells
of postcapillary venules, glycosamino-
glycan-binding diffusible activators of
inflammation such as chemokines de-
signed to act locally, and short-lived
proinflammatory molecules such as
prostaglandins, nitric oxide, and reactive
oxygen intermediates, the molecular
regulation of the inflammatory response
could be explained at the cellular level.
The idea that the CNS can regulate
inflammation—i.e., that emotional stress
can exacerbate inflammatory bowel
disease, arthritis, etcetera, whereas a
positive mental attitude gets one over
physical infirmities—has been around for
a long time. However, the scientific basis
of this phenomenon has come to light
relatively recently. Lymphocytes, myeloid
cells, and endothelial cells bear receptors
for and respond to growth factors, cyto-
kines, and neurotransmitters that were
originally thought to be specific for the
nervous system (Wong et al., 2002). There
is good evidence for bidirectional com-
munication between the nervous system
and the immune system (Andersson and
Tracey, 2012).
The sympathetic nervous system (more
properly, adrenergic stimulation) has
been shown to play a major role in regu-
lating the inflammatory response. Adren-
ergic neurotransmitters and hormones(acting through adrenergic b2 receptors)
are traditionally thought of as anti-inflam-
matory, which fits with their stimulation
by the response-to-injury physiology of
the ‘‘fight-or-flight’’ response. However,
proinflammatory actions of adrenergic
neurons have been described (Arima
et al., 2012).
The parasympathetic nervous system
regulates a ‘‘cholinergic anti-inflamma-
tory pathway’’ (Andersson and Tracey,
2012) that is particularly potent in limiting
the continued secretion of cytokines
such as tumor necrosis factor alpha
(TNF-a) by peripheral tissues. Macro-
phages have nicotinic receptors for the
neurotransmitter acetylcholine, which is
secreted in inflamed tissue by branches
of the vagus nerve. Upon binding acetyl-
choline, these receptors transduce a
signaling pathway that inhibits NF-kB
activation and dampens the proinflamma-
tory signals from toll-like receptors and
cytokines (Andersson and Tracey, 2012).
The anti-inflammatory effects of parasym-
pathetic stimulation are pathophysiologi-
cally relevant. Stimulation of this pathway
can protect rodents from the proinflam-
matory mediators released in response
to hemorrhagic shock (Luyer et al.,
2005). These effects can be ablated by
vagotomy or pharmacologic blockade of
the receptors., August 24, 2012 ª2012 Elsevier Inc. 189
